Detalhe da pesquisa
1.
Suppression of Enhancer Overactivation by a RACK7-Histone Demethylase Complex.
Cell
; 165(2): 331-42, 2016 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27058665
2.
Deubiquitinase USP20 promotes breast cancer metastasis by stabilizing SNAI2.
Genes Dev
; 34(19-20): 1310-1315, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32943575
3.
The HLA-I landscape confers prognosis and antitumor immunity in breast cancer.
Brief Bioinform
; 25(3)2024 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38602320
4.
Superenhancer drives a tumor-specific splicing variant of MARCO to promote triple-negative breast cancer progression.
Proc Natl Acad Sci U S A
; 119(46): e2207201119, 2022 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36343244
5.
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
Lancet Oncol
; 25(2): 184-197, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38211606
6.
HER2-low heterogeneity between primary and paired recurrent/metastatic breast cancer: Implications in treatment and prognosis.
Cancer
; 130(6): 851-862, 2024 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37933913
7.
Molecular Profiling Provides Clinical Insights Into Targeted and Immunotherapies as Well as Colorectal Cancer Prognosis.
Gastroenterology
; 165(2): 414-428.e7, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37146911
8.
Secretory breast carcinoma: clinicopathological features and prognosis of 52 patients.
Breast Cancer Res Treat
; 203(3): 543-551, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37897648
9.
Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: exploring chidamide and enzalutamide as a promising combination strategy.
Cancer Cell Int
; 24(1): 131, 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38594722
10.
Elongin B promotes breast cancer progression by ubiquitinating tumor suppressor p14/ARF.
Cell Biol Toxicol
; 40(1): 24, 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38653919
11.
In vivo CRISPR screens identify RhoV as a pro-metastasis factor of triple-negative breast cancer.
Cancer Sci
; 114(6): 2375-2385, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36898847
12.
Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study.
Oncologist
; 28(1): 86-e76, 2023 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36426808
13.
Ipsilateral breast tumor recurrence after breast-conserving surgery: insights into biology and treatment.
Breast Cancer Res Treat
; 202(2): 215-220, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37528263
14.
High expression of TLR3 in triple-negative breast cancer predicts better prognosis-data from the Fudan University Shanghai Cancer Center cohort and tissue microarrays.
BMC Cancer
; 23(1): 298, 2023 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37005579
15.
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
Future Oncol
; 19(35): 2349-2359, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37526149
16.
Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial.
Mol Cancer
; 21(1): 84, 2022 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35337339
17.
RNA binding protein POP7 regulates ILF3 mRNA stability and expression to promote breast cancer progression.
Cancer Sci
; 113(11): 3801-3813, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35579257
18.
De-escalation of five-year adjuvant endocrine therapy in patients with estrogen receptor-low positive (immunohistochemistry staining 1%-10%) breast cancer: Propensity-matched analysis from a prospectively maintained cohort.
Cancer
; 128(9): 1748-1756, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35213037
19.
The early-stage triple-negative breast cancer landscape derives a novel prognostic signature and therapeutic target.
Breast Cancer Res Treat
; 193(2): 319-330, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35334008
20.
Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?
Breast Cancer Res Treat
; 196(1): 97-109, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36040640